CISATRACURIUM BESYLATE INJECTION SOLUTION

Страна: Канада

Език: английски

Източник: Health Canada

Активна съставка:

CISATRACURIUM (CISATRACURIUM BESYLATE)

Предлага се от:

ACCORD HEALTHCARE INC

АТС код:

M03AC11

INN (Международно Name):

CISATRACURIUM

дозиране:

2MG

Лекарствена форма:

SOLUTION

Композиция:

CISATRACURIUM (CISATRACURIUM BESYLATE) 2MG

Начин на приложение:

INTRAVENOUS

Броя в опаковка:

10 ML

Вид предписание :

Prescription

Терапевтична област:

NEUROMUSCULAR BLOCKING AGENTS

Каталог на резюме:

Active ingredient group (AIG) number: 0133260001; AHFS:

Статус Оторизация:

APPROVED

Дата Оторизация:

2016-09-01

Данни за продукта

_Cisatracurium Besylate Injection_
_ Product Monograph Page 1 of 32 _
PRODUCT MONOGRAPH
PR
CISATRACURIUM BESYLATE INJECTION
Solution for injection; 20 mg / 10 mL (2 mg / mL) cisatracurium (as
cisatracurium besylate)
(Multiple dose vial)
House Standard
NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT
Sterile solution
THIS DRUG SHOULD BE ADMINISTERED ONLY BY ADEQUATELY TRAINED
PROFESSIONALS FAMILIAR WITH ITS
ACTIONS, CHARACTERISTICS, AND HAZARDS.
Accord Healthcare Inc.
3535 boul. St. Charles, Suite 704
Kirkland, QC H9H 5B9
Canada
Submission Control No: 180494
Date of Preparation:
August 31, 2016
_Cisatracurium Besylate Injection_
_ Product Monograph Page 2 of 32 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION........................................................3
SUMMARY PRODUCT INFORMATION
.....................................................................3
INDICATIONS AND CLINICAL USE
...........................................................................3
CONTRAINDICATIONS
................................................................................................3
WARNINGS AND
PRECAUTIONS...............................................................................4
ADVERSE
REACTIONS.................................................................................................9
DRUG INTERACTIONS
................................................................................................10
DOSAGE AND ADMINISTRATION
............................................................................11
OVERDOSAGE
..............................................................................................................17
ACTION AND CLINICAL PHARMACOLOGY
..........................................................17
STORAGE AND
STABILITY........................................................................................24
SPECIAL HANDLING INSTRUCTIONS
.....................................................................24
DOSAGE FORMS, COMPOSITION AND PACKAGING
....................